… erlotinib and gefitinib are considered equivalent. However, the recommended dose of gefitinib…
Although there was no difference in plasma erlotinib concentration between the cohorts (P …

… Several EGFR tyrosine kinase inhibitors (TKIs), including erlotinib and gefitinib, have
been approved for the treatment of patients with EGFR mutation-positive advanced NSCLC. …

… study is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of
gefitinib… was not a pre-requisite for response to salvage erlotinib treatment in our study cohort. …

… (gefitinib or erlotinib) studied, given that all patients in the East Asian cohorts and our
present study were treated with gefitinib … those treated with erlotinib or gefitinib. Although the …

… cohorts [10,16]. In contrast, most such studies did observe PFS prolonging for study cohorts,
… in such clinical cases, with gefitinib/erlotinib being the baseline reference therapy for all …

… The results of the study show that afatinib therapy was superior to erlotinib and gefitinib as
first-… type used was an analytic observational retrospective cohort study. The subjects of the …

… ) had prolonged survival with erlotinib treatment.Similarly, patients with EGFR IHC-positive
or EGFR FISH-positive tumors had superior survival with gefitinib compared with placebo.…

… first-generation EGFR TKIs (eg, gefitinib and erlotinib) is approximately 10 to 12 months.10, …
, is a superior first-line therapy according to the FLAURA study, 11 , 12 there is no standard …

… gefitinib, 1,599 erlotinib, and 1,512 afatinib) as first-line therapy were included in our study
(… To the best of our knowledge, this study is the single largest cohort study to investigate the …

… A large cohort study based on the Taiwan Cancer Registry, conducted in 2011–2015,
compared the efficacy of three different TKIs—gefitinib, erlotinib, and afatinin. The results showed …